Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives
Journal of Robotic Surgery · 2025
DOI: 10.1007/s11701-025-03038-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Robotic Surgery, 2025. Verfasst von Vittorio Imperatore und 12 weiteren Autor:innen. Beteiligte Einrichtung: UOC Urologia, AORN Moscati, Avellino, Italy. Hauptthemen laut MEDLINE: Testicular Neoplasms, Lymph Node Excision, Robotic Surgical Procedures, Neoplasms, Germ Cell and Embryonal. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Robot-assisted retroperitoneal lymph node dissection (R-RPLND) is an increasingly adopted minimally invasive option for carefully selected patients with testicular germ-cell tumours. We performed a narrative (non-systematic) review of retrospective single- and multicentre cohorts from high-volume programmes to appraise peri-operative safety, functional preservation, and oncologic control in primary and post-chemotherapy settings. In primary disease (typically clinical stage I–IIA/B), representative medians across series from expert centres include estimated blood loss of ~ 50 to 200 mL, hospital stay of 1–2 days, and nodal yields of ~ 19 to 32; major complications (Clavien–Dindo ≥ III) are uncommon (~ 0 to 10%), and antegrade ejaculation is usually preserved (often ≥ 85 to 100%) when nerve-sparing templates are applied. In post-chemotherapy cohorts—generally limited to smaller, peripherally located residual masses with favourable biology—robotic RPLND is feasible but technically demanding, with reported conversion rates of ~ 0 to 13% and major complication rates of ~ 10 to 20%; chylous complications remain a notable risk. Across available retrospective comparative series, including propensity-matched cohorts, R-RPLND has been associated with lower estimated blood loss and shorter hospitalisation than open RPLND (for example, ~ 200 vs 300 mL and 1 vs 5 days in a matched primary cohort; ~ 235 vs 825 mL and 2 vs 7 days in post-chemotherapy series), at the cost of longer operative time, while nodal yields and short-term oncologic outcomes appear comparable; these non-randomised data are descriptive and subject to selection and centre bias rather than proof of causality. For carefully staged seminoma IIA/B (≤ 3 cm nodes), contemporary guidelines permit RPLND as a chemotherapy-sparing option (Moderate recommendation; Evidence Level B), consistent with phase II data showing high 2–3-year disease control after primary RPLND. Centralisation and experience are critical: population-based analyses suggest fewer in-hospital complications and shorter hospital stays with robotic cases, and learning-curve data show improving efficiency and safety as programmes mature. Overall, when undertaken by experienced teams in high-volume centres, R-RPLND offers low blood loss, short hospitalisation, favourable ejaculatory outcomes, and low in-field recurrence for appropriately selected patients, while requiring judicious case selection and a low threshold for conversion in technically demanding post-chemotherapy disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UOC Urologia, AORN Moscati, Avellino, Italy.
- Urology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy. carmeloquattrone@hotmail.it.
- Urology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy.
- Unit of Urology, AORN Antonio Cardarelli, Naples, Italy.
- Casa di Cura Nostra Signora di Lourdes, Naples, Italy.
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy.
Zitieren
APA
Imperatore, V., Quattrone, C., Bottone, F., Romeo, G., Ruffo, A., Esposito, F., Di Girolamo, A., Giannella, R., Crocetto, F., Napolitano, L., Sciorio, C., Manfredi, C., & Spirito, L. (2025). Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives. Journal of Robotic Surgery. https://doi.org/10.1007/s11701-025-03038-1
Vancouver
Imperatore V, Quattrone C, Bottone F, Romeo G, Ruffo A, Esposito F, et al. Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives. Journal of Robotic Surgery. 2025. doi:10.1007/s11701-025-03038-1
BibTeX
@article{Imperatore2025,
author = {Imperatore, Vittorio and Quattrone, Carmelo and Bottone, Francesco and Romeo, Giuseppe and Ruffo, Antonio and Esposito, Fabio and Di Girolamo, Antonio and Giannella, Riccardo and Crocetto, Felice and Napolitano, Luigi and Sciorio, Carmine and Manfredi, Celeste and Spirito, Lorenzo},
title = {Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives},
journal = {Journal of Robotic Surgery},
year = {2025},
doi = {10.1007/s11701-025-03038-1}
}
EUVIMED